Menu
← Oncology Approval Tracker
FDA DECISION ·
Bosutinib 400 mg tablets
bosutinib monohydrate · MSN Laboratories
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Final generic approval of the 400 mg Bosulif tablet. Labeled uses include chronic-phase Philadelphia chromosome-positive CML in adults and children age 1 or older who are newly diagnosed or resistant or intolerant to prior therapy, and accelerated- or blast-phase CML in resistant or intolerant adults.
LAMPGEN ANALYSIS
Why it matters
FDA approved generic 100 and 500 mg tablets under another application in 2025. This action added a finally approved 400 mg tablet for the labeled CML uses.
What research teams should watch
Distinguish tablet strengths and applicable FDA application actions. Verify product availability and document the phase of CML and prior-treatment response.
PRIMARY RECORDS